Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Menaquinone-7
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Gnosis by Lesaffre
Deal Size : Undisclosed
Deal Type : Acquisition
Gnosis by Lesaffre Enhances Vitamin K2 Offering with Acquisition of NattoPharma
Details : This acquisition brings together globally recognized vitamin K2 brands vitaMK7® and MenaQ7® and allows Gnosis by Lesaffre to offer to the market the most complete portfolio of solutions, adapted to each market need and able to satisfy all customers.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
May 25, 2021
Lead Product(s) : Menaquinone-7
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Gnosis by Lesaffre
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Menaquinone-7
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Undisclosed
Recipient : Aristotle University Of Thessaloniki
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
May 25, 2021
Lead Product(s) : Menaquinone-7
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Recipient : Aristotle University Of Thessaloniki
Deal Size : Inapplicable
Deal Type : Inapplicable